Kite and Arcellx Announce Expansion in Strategic Partnership

Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced that the companies have expanded their existing collaboration, which was originally announced in December 2022. Kite has exercised its option to negotiate a license for Arcellx’s ARC-SparX program, ACLX-001, in multiple ...

Related Keywords

California ,United States ,Foster City ,Santa Monica ,Cindy Perettie ,Wilson Sonsini Goodrich Rosati ,Arcellx Inc ,Drug Administration ,Linkedin ,Securities Exchange ,Gilead Sciences ,Exchange Commission ,Twitter ,Nasdaq ,Gilead Sciences Inc ,Gilead Company ,Executive Vice President ,Rami Elghandour ,Chief Executive ,Hart Scott Rodino Antitrust Improvement Act ,Sonsini Goodrich ,Fast Track ,Orphan Drug ,Regenerative Medicine Advanced Therapy ,Securities Act ,Securities Exchange Act ,Collaboration Agreement ,Risk Factors ,Quarterly Report ,Private Securities Litigation Reform Act ,